Imagenetix announces positive safety studies on anti-inflammatory compound 1-TDC

By Elaine Rigoli

Tampa, Fla., June 1 - Imagenetix Inc. announced that its proprietary anti-inflammatory compound, 1-tetradecanol complex (1-TDC), intended for use in the treatment of periodontal disease and other widespread inflammatory conditions, has achieved expected results in important baseline acute toxicity studies.

In the first study, CD-1 mice were administered 1-TDC orally at a dose equal to 31.5/kg body weight, or 1,500 times the suggested human dose, according to a news release.

Animals were gavaged daily for a total of seven days, then euthanized using standard laboratory procedures with major organs harvested for histological examination.

The findings showed no histological changes to any of the animals' main organs and no adverse events, toxicity or abnormal behavior elicited in the animals at any time during this study.

In the second study, Golden Syrian hamsters were used to determine the potential of 1-TDC for inducing oral mucosa irritation.

For all animals, one side served as control with one side exposed to the given agent. Three hamsters served as controls and were dosed with cottonseed oil as sham controls.

Treatment animals were dosed with 1-TDC. All animals were dosed four times with the given agent. Exposure to each agent lasted for four hours.

The cheek pouches were examined and scored for irritation prior to and after each dose. In addition, tissue samples were harvested and examined by a veterinary pathologist for histological change.

The compound, 1-TDC, did not elicit adverse events or histological changes in the treatment animals when compared to animal control or sham control and therefore considered safe.

Based in San Diego, Imagenetix develops and markets natural-based, proprietary products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.